The Cox-2 inhibitors cause fewer gastrointestinal side effects, including upset stomach, heartburn and ulcers, than other pain-relieving drugs.
E-mails suggest otherwise.
The study found that high doses of Vioxx, known as rofecoxib, tripled risks of heart attacks and sudden cardiac death.
FDA: http://www.fda.gov/
Or were they persuaded to do so by Merck's advertising?
The solution is not a total ban on advertising, as some suggest, but rather more clinical trials of drugs, aimed specifically at determining effectiveness as well as long-term safety.
(On Friday, Pfizer Inc. issued a warning that its Cox-2 drug Bextra may increase cardiovascular risk for some patients.)
